Shigeaki Kato
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Shigeaki Kato has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- Kazuhiro Uenishi
Laboratory of Physiological Nutrition, Kagawa Nutrition University
2 shared publications - M. Tokiwa
Clinical Development Department, IDD Inc., Tokyo, Japan
2 shared publications - Masataka Shiraki
Research Institute and Practice for Involutional Diseases Nagano Japan
2 shared publications Alexander Kouzmenko
Research Institute of Innovative Medicine, Tokiwa Foundation, Jyoban Kamiyunagayamachi, Iwaki, Japan
1 shared publicationJinichi Mori
Center for Regional Cooperation, Iwaki Meisei University, Iwaki, Japan
1 shared publicationKoichi Nishimura
Center for Regional Cooperation, Iwaki Meisei University, Iwaki, Japan
1 shared publication
Latest Publications
- Open Access
- 1 January 2019
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 26 (1) , 3-12
The Function of the Vitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic Regulation of Target Genes: Implications for Bone Metabolism
Sawatsubashi S, et al. J Bone Metab. 2019 Feb;26(1):3-12. https://doi.org/10.11005/jbm.2019.26.1.3
- 1 January 2019
- Published by Korean Society for Bone and Mineral Research in Journal of Bone Metabolism
- Vol. 26 (1) , 3-12
Open AccessThe Function of the Vitamin D Receptor and a Possible Role of Enhancer RNA in Epigenomic Regulation of Target Genes: Implications for Bone Metabolism
Sawatsubashi S, et al. J Bone Metab. 2019 Feb;26(1):3-12. https://doi.org/10.11005/jbm.2019.26.1.3
- Open Access
- 26 February 2018
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (5) , 1225
Correction to: Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
There were two errors in this article. 1. In the section “Ethical considerations”, the registration number of the study was incorrectly given as UMIN000024492. The correct number is UMIN0000 20267....
- 26 February 2018
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (5) , 1225
Open AccessCorrection to: Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
There were two errors in this article. 1. In the section “Ethical considerations”, the registration number of the study was incorrectly given as UMIN000024492. The correct number is UMIN0000 20267....
- Open Access
- 23 December 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (3) , 723-732
Stimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
Summary Intestinal fractional calcium absorption (FCA) was assessed before and after vitamin D3 treatment. Serum 1,25(OH)2D concentration was significantly increased by plain vitamin D3 and reduced by eldecalcitol. The 1α hydroxyl calcidiol and eldecalcitol treatments increased FCA, which may be induced through direct stimulation of vitamin D receptors in the intestine. Introduction To assess the effects of vitamin D3 compounds on intestinal FCA and calcium-regulating hormones in post-menopausal osteoporosis, a randomized open-label prospective study was conducted. Methods Forty eligible patients were allocated randomly into four groups: eldecalcitol (ELD; 0.75 μg/day), 1α hydroxyl calcidiol (ALF; 1 μg/day), plain vitamin D3 (800 IU/day), and control. Before and after the 4-week treatment, intestinal FCA was estimated by using a double isotope method, and serum concentrations of calcium-regulating hormones and a bone turnover marker were measured. Results The baseline FCA value of the participants was 21.5 ± 7.9% (mean ± SD) and was significantly correlated with serum 1,25(OH)2D (calcitriol) concentration. After the treatment, the FCA significantly increased by 59.5% (95% CI, 41.6 to 77.4%) in the ELD group and by 45.9% (27.9 to 63.8%) in the ALF group, whereas no significant change in the plain vitamin D3 group was found. Unlike the baseline FCA, post-treatment FCA exhibited no significant correlation with serum calcitriol concentration. Parathyroid hormone levels were suppressed by ALF and plain vitamin D3 but were sustained in the ELD and control groups. Serum calcitriol tended to be suppressed by ELD, whereas plain vitamin D3 treatment increased both serum 25(OH)D and calcitriol concentrations. Conclusion These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not. Those effects of vitamin D3 compounds on FCA were independent of serum calcitriol concentration, suggesting that ALF and ELD may directly stimulate intestinal vitamin D receptors.
- 23 December 2017
- Published by Springer Nature in Osteoporosis International
- Vol. 29 (3) , 723-732
Open AccessStimulation of intestinal calcium absorption by orally administrated vitamin D3 compounds: a prospective open-label randomized trial in osteoporosis
Summary Intestinal fractional calcium absorption (FCA) was assessed before and after vitamin D3 treatment. Serum 1,25(OH)2D concentration was significantly increased by plain vitamin D3 and reduced by eldecalcitol. The 1α hydroxyl calcidiol and eldecalcitol treatments increased FCA, which may be induced through direct stimulation of vitamin D receptors in the intestine. Introduction To assess the effects of vitamin D3 compounds on intestinal FCA and calcium-regulating hormones in post-menopausal osteoporosis, a randomized open-label prospective study was conducted. Methods Forty eligible patients were allocated randomly into four groups: eldecalcitol (ELD; 0.75 μg/day), 1α hydroxyl calcidiol (ALF; 1 μg/day), plain vitamin D3 (800 IU/day), and control. Before and after the 4-week treatment, intestinal FCA was estimated by using a double isotope method, and serum concentrations of calcium-regulating hormones and a bone turnover marker were measured. Results The baseline FCA value of the participants was 21.5 ± 7.9% (mean ± SD) and was significantly correlated with serum 1,25(OH)2D (calcitriol) concentration. After the treatment, the FCA significantly increased by 59.5% (95% CI, 41.6 to 77.4%) in the ELD group and by 45.9% (27.9 to 63.8%) in the ALF group, whereas no significant change in the plain vitamin D3 group was found. Unlike the baseline FCA, post-treatment FCA exhibited no significant correlation with serum calcitriol concentration. Parathyroid hormone levels were suppressed by ALF and plain vitamin D3 but were sustained in the ELD and control groups. Serum calcitriol tended to be suppressed by ELD, whereas plain vitamin D3 treatment increased both serum 25(OH)D and calcitriol concentrations. Conclusion These findings suggest that oral administration of vitamin D3 analogues (ALF and ELD) stimulates FCA but plain vitamin D3 does not. Those effects of vitamin D3 compounds on FCA were independent of serum calcitriol concentration, suggesting that ALF and ELD may directly stimulate intestinal vitamin D receptors.